Billion-euro deal in the US pharmaceutical industry
Johnson & Johnson wants Intra-Cellular Therapies for a total of around 14.6 billion US dollars and strengthen its position in the field of drugs for neurological diseases. According to the US pharmaceutical and medical technology group, it intends to offer 132 dollars per share in cash.
The takeover is intended to expand the portfolio by lumateperone an oral treatment for adults with schizophrenia and depressive episodes associated with bipolar I or II disorder. The acquisition also includes ITI-1284, a Phase 2 compound being studied in generalized anxiety disorder and psychosis and agitation associated with Alzheimer's disease, as well as a broader pipeline that aligns with Johnson & Johnson's current areas of focus. Shares of Intra-Cellular Therapies surged 35 percent to 128 dollars in pre-market US trading.
Source:
